Pre-treatment endocrine-nutritional signatures predict clinical benefit from PD-1/PD-L1 blockade in hematologic malignancies - PubMed
4 hours ago
- #immunotherapy
- #biomarkers
- #hematologic malignancies
- Pre-treatment endocrine-nutritional signatures can predict the clinical benefit of PD-1/PD-L1 blockade in hematologic malignancies.
- PD-1/PD-L1 inhibitors show high efficacy in classical Hodgkin lymphoma (cHL) and primary mediastinal large B-cell lymphoma (PMBCL), but limited success in multiple myeloma and leukemias.
- Dysregulated hormones (e.g., cortisol, thyroid hormones, sex steroids) and nutritional status (e.g., vitamin D, zinc) influence immunotherapy outcomes by modulating T-cell exhaustion and tumor microenvironment dynamics.
- Hypercortisolism, hypothyroidism, insulin resistance, vitamin D deficiency, and hypoalbuminemia correlate with poorer immunotherapy outcomes, while thyroid immune-related adverse events and moderate obesity may predict benefit.
- Integrated signatures like the Glasgow Prognostic Score and Prognostic Nutritional Index offer superior prognostic value and enable targeted interventions to enhance immunotherapy efficacy.
- Mechanistic insights suggest these endocrine-nutritional factors converge on mTOR/IFN-γ pathways and microbiome modulation, offering potential for personalized immunotherapy approaches.